Newsletters

12.20.23

Supreme Court Will Hear Medication Abortion Case; Three States Ask to Intervene in District Court

On December 13, 2023, the Supreme Court announced its intention to review the August 16 ruling by the Fifth Circuit in Alliance for Hippocratic Medicine (AHM) v. U.S. Food and Drug Administration, et al. (AHM v. FDA), marking the Court’s first return to the abortion debate since overturning ...


12.12.23

Trials & Tribulations: Removing Barriers to Participation in Clinical Trials to Advance Innovation

Through clinical trials, eligible patients can receive the latest cutting-edge treatments, which may not yet be available nationwide.


08.21.23

5th Circuit Rejects FDA Actions Expanding Access to Medication Abortion; Supreme Court Review Likely

On Wednesday, August 16, the Fifth Circuit Court of Appeals issued a ruling upholding parts of a Texas district court’s decision that would, if it becomes effective, severely limit access to mifepristone, one of two pills taken in a medication abortion.


06.05.23

Prenatal Vaccines in Medicaid and CHIP: Coverage, Reimbursement and State Policy Solutions

In a new white paper funded by Pfizer, Inc., Manatt Health discusses the current landscape of Medicaid and Children’s Health Insurance Program coverage and reimbursement for prenatal vaccines, informed by a recent assessment of relevant policies in all 50 states, plus Washington, D.C., and ...


05.26.23

Debt Limit Negotiations Continue and Health Care Stakeholders Consider the Implications of a Breach

The Department of the Treasury (the Treasury) has indicated that absent congressional action to suspend or raise the debt limit, the federal government will likely be unable to satisfy all of its financial obligations as early as June 1—the so-called “X Date.”


05.17.23

CMS Proposes Significant Medicaid Policy Changes for Access Monitoring, Managed Care, and HCBS

On Thursday, April 27, the Centers for Medicare & Medicaid Services (CMS) released two highly anticipated proposed rules.


05.10.23

Upcoming Regulatory Changes Associated With the End of the PHE

At 11:59 p.m. on Thursday, May 11, 2023, the COVID-19 public health emergency declaration will conclude, more than three years after taking effect in January 2020.


04.14.23

Federal Courts Divided: Medication Abortion and the Uncertain Future of FDA’s Drug Oversight

Less than one year after the Supreme Court overturned the federal constitutional right to abortion in Dobbs v. Jackson Women’s Health Organization and “returned [the issue of abortion back] to the people and their elected representatives,” access to safe and legal abortion ...


04.05.23

District Court Blocks ACA Provision Mandating Coverage of Preventive Services

The Affordable Care Act requirement for commercial coverage of certain preventive services without cost sharing is unenforceable, according to a March 30 decision in Braidwood Management, Inc. v. Becerra by Judge Reed O’Connor in the U.S. District Court, Northern District of Texas.


02.13.23

What Changes if the COVID-19 Public Health Emergency Ends May 11

The Biden Administration has announced that May 11, 2023, will be the final day of the COVID-19 public health emergency (PHE) declaration, which has been in effect since January 2020.